Cart
sales@molnova.com
Pipamperone
CAS No. 1893-33-0
Pipamperone( Floropipamide | McN-JR 3345 | R 3345 )
Catalog No. M26378 CAS No. 1893-33-0
Pipamperone binds 5-HT2A closely as receptor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 126 | In Stock |
|
| 2MG | 73 | In Stock |
|
| 5MG | 116 | In Stock |
|
| 10MG | 169 | In Stock |
|
| 25MG | 282 | In Stock |
|
| 50MG | 421 | In Stock |
|
| 100MG | 609 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePipamperone
-
NoteResearch use only, not for human use.
-
Brief DescriptionPipamperone binds 5-HT2A closely as receptor.
-
DescriptionPipamperone binds 5-HT2A closely as receptor.
-
In Vitro——
-
In Vivo——
-
SynonymsFloropipamide | McN-JR 3345 | R 3345
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1893-33-0
-
Formula Weight375.488
-
Molecular FormulaC21H30FN3O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (266.33 mM)
-
SMILESNC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ono M, Kanemaru Y, Yasuda S, Okawa M, Kinjo J, Miyashita H, Yokomizo K, Yoshimitsu H, Nohara T. A new resin glycoside from Calystegia soldanella and its antiviral activity towards herpes. Nat Prod Res. 2017 Nov;31(22):2660-2664. doi: 10.1080/14786419.2017.1280492. Epub 2017 Jan 20. PubMed PMID: 28105860.
molnova catalog
related products
-
D(+)-Glucuronic acid...
Glucuronic acid is a carboxylic acid and highly soluble in water. In humans glucuronic acid is often linked to toxic or poisonous substances to allow for subsequent elimination and to hormones to allow for easier transport.
-
Neuronostatin-19 (mo...
Neuronostatin-19 (mouse, rat)
-
Tetradehydrothalictr...
Tetradehydrothalictrifoline is a nature product.
